Bioinvent International Ab

This study tests a new drug (BI-1206) combined with an approved immunotherapy (pembrolizumab) in people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the combination is safe and can help control the cancer. About 197 adults w…

This early-stage trial tests a new drug called BI-1808, alone or with pembrolizumab, in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard therapy. The main goals are to check safety, find the best dose, and see if…